| Page 2 | Aplastic Anemia and MDS International Foundation

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes

Author(s): 
Santini V
Primary Author: 
Santini V
Journal Title: 
Clin Lymphoma Myeloma Leuk
Original Publication Date: 
May 2018

In the past few months, 2 main streams of research have dominated the panorama of myelodysplastic syndrome (MDS) investigations: deepening the insight into the pathogenic role, hierarchy, and prognostic effect of somatic mutations and, as a consequence, into the effect of inherited congenital predisposing conditions and the second, quite interlinked with the first, analyzing inflammation and innate immunity in patients with MDS.

Bone Marrow Diseases: 

A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia

Author(s): 
Bryant AL, Drier SW, Lee S, Bennett AV
Primary Author: 
Bryant AL
Journal Title: 
Leuk Res
Original Publication Date: 
Jun 2018

The purpose of this systematic literature review was to identify clinical trials of MDS and AML that included patient-reported outcome (PRO) instruments, and to summarize the symptom and other health related quality of life (HRQOL) concepts most frequently assessed and the PRO instruments that were used. Sixteen manuscripts describing 14 distinct trials met all criteria (i.e., phase 2 or 3

Bone Marrow Diseases: 

Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

Author(s): 
Bell JA, Galaznik A, Blazer M, Farrelly E, Ogbonnaya A, Raju A, Eaddy M, Fram RJ, Faller DV
Primary Author: 
Bell JA
Journal Title: 
Leuk Lymphoma
Original Publication Date: 
Jun 2018

Most higher-risk myelodysplastic syndrome (HR-MDS) patients will become transfusion-dependent, leading to potential complications, including infections or end-organ dysfunction. Data correlating achievement of transfusion-free intervals (TFIs) during first-line therapy (1LT) with survival are sparse. We evaluated HR-MDS patients receiving 1LT diagnosed from 1/1/2008 to 7/31/2015 and the impact of a TFI (≥60-day interval without transfusions) on progression-free and overall survival (PFS, OS) using Cox proportional-hazard models.

Bone Marrow Diseases: 

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis

Author(s): 
Migdady Y, Barnard J, Al Ali N, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Komrokji RS
Primary Author: 
Migdady Y
Journal Title: 
Clin Lymphoma Myeloma Leuk
Original Publication Date: 
May 2018

ACKGROUND:

Bone Marrow Diseases: